StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.DE price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Viridian Therapeutics, Inc.DE's price to sales ratio was 49.8× on Nov 11, 2026, against 37.1× a year earlier. Over the last 5 years it ranged from 3.5× to 488.3×, with a median of 35.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202649.8×+13.6
2025Dec 31, 202536.1×−334.3
2023Oct 31, 2023370.4×+187.1
2022Jul 29, 2022183.3×+46.6
2021Dec 31, 2021136.7×+103.3
2020Dec 31, 202033.4×+29.7
2019Dec 31, 20193.7×−6.6
2018Dec 31, 201810.3×−58.5
2017Dec 29, 201768.8×+67.8
2016Dec 30, 20161.0×−0.7
2015Dec 31, 20151.7×+1.6
2014Dec 31, 20140.1×–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?